Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
Klinik für Urologie und Kinderurologie
Leitung: Prof. Dr. Michael Stöckle
Sie befinden sich hier: >> Startseite >> Klinische Zentren und Einrichtungen >> Klinische Zentren und Einrichtungen am UKS >> Urologie >> Publikationen

Wissenschaftliche Publikationen

Publikationen 2019

Stubendorff B, Wilhelm K, Posselt K, Catto J, Hartmann A, Bertz S, Füssel S, Novotny V, Toma M, Gajda M, Lehmann J, Wunderlich H, Grimm MO, Stöckle M, Junker K (2019). A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. J Cancer Res Clin Oncol.


Zeuschner P, Ueberdiek S, Pryalukhin A, Veith C, Saar M, Smola S, Bohle RM, Junker K, Stöckle M, Heinzelbecker J Human Papillomavirus-Associated Invasive Condylomas in a Man with Immunosuppressive Comorbidities.
(2018). Urol Int. 2019

Hajili T, Ohlmann CH, Linxweiler J, Niklas C, Janssen M, Siemer S, Stoeckle M, Saar M. (2018). Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: Results of a single-institution series with long-term follow up. BJU Int 123:58–64


Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M (2019). Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol.


Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Höfler H, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Haferkamp A, Geppert CI, Stöhr C, Hartmann A (2019). High proliferation rate and TNM-stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. Hum Pathol

Publikationen 2018

Linxweiler J, Hammer M, Muhs S, Kohn M, Pryalukhin A, Veith C, Bohle RM, Stöckle M, Junker K, Saar M (2018). Patient-derived, three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer. J Cancer Res Clin Oncol.

Crossey F, Marx S, Hölters S, Schmitt K, Bohle RM, Schmidt T, Stöckle M, Sester U, Sester M, Janssen MWW.
Robust method for isolation of tumor infiltrating lymphocytes with a high vital cell yield from small samples of renal cell carcinomas by a new collagenase-free mechanical procedure.
Urol Oncol. 2018  S1078-1439(18)30201-1.


Stöckle M, Junker K, Fornara P (2018). Low-risk Prostate Cancer Prior to or After Kidney Transplantation. Eur Urol Focus 4(2):148-152

Linxweiler J, Shayesteh-Kheslat R, Fries P, Schneider G, Janssen M, Ohlmann CH, Stöckle M, Siemer S, Saar M (2018). Organ-Preserving Surgical Treatment of a Horseshoe Kidney Occupied by a Large Renal Cell Carcinoma with Extensive Venous Invasion: A Case Report. Urol Int.  100(2):245-247


Ernst S, Saar M, Brenneis H, Kubale R, Ueberdiek S, Ohlmann CH, Stoeckle M, Heinzelbecker J (2018). Segmental Testicular Infarction: Case Series and Literature Review of a Rare Diagnosis in Men with Acute Testicular Pain. Urol Int. 101(1):114-116


Heinzelbecker J, Stöckle M (2018). Re: Follow-up of Prostatectomy Versus Observation for Early Prostate Cancer. Eur Urol. 73(2):303-304.


Janssen MWW, Linxweiler J, Philipps I, Bütow Z, Siemer S, Stöckle M, Ohlmann CH (2018). Kidney autotransplantation after nephrectomy and work bench surgery as an ultimate approach to nephron-sparing surgery. World J Surg Oncol. 16(1):35


Linxweiler J, Saar M, Al-Kailani Z, Janssen M, Ezziddin S, Stöckle M, Siemer S, Ohlmann CH (2018). Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: perioperative and early oncological outcomes. Surg Oncol 27(2):138-145


Loertzer P, Siemer S, Stöckle M, Ohlmann CH (2018). Robot-sewn ileoileal anastomosis during robot-assisted cystectomy. W J Urol 36(7):1079-1084


Ohlmann CH, Gross-Langenhoff M (2018). Efficacy and Tolerability of Leuprorelin Acetate (Eligard®) in Daily Practice in Germany: Pooled Data from 2 Prospective, Non-Interventional Studies with 3- or 6-Month Depot Formulations in Patients with Advanced Prostate Cancer. Urol Int. 100(1):66-71


Linxweiler J, Körbel C, Müller A, Hammer M, Veith C, Bohle RM, Stöckle M, Junker K, Menger MD, Saar M (2018). A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases. Prostate. 78(9):664-675


Janssen MWW, Linxweiler J, Terwey S, Rugge S, Ohlmann CH, Becker F, Thomas C, Neisius A, Thüroff JW, Siemer S, Stöckle M, Roos FC (2018). Survival outcomes in patients with large (≥7cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: Results of a multicenter cohort with long-term follow-up. PLoS One 13(5):e0196427


Breda A, Territo A, Gausa L, Tugcu V, Alcaraz A, Musquera M, Decaestecker K, Desender L, Stockle M, Janssen M, Fornara P, Mohammed N, Siena G, Serni S, Guirado S, Facundo C, Doumerc N (2018). Robot-assisted Kidney Transplantation: The European Experience. Eur Urol. 73(2):273-281


Awwad HM, Ohlmann CH, Stoeckle M, Geisel J, Obeid R (2018). Serum concentrations of folate vitamers in patients with a newly diagnosed prostate cancer or hyperplasia. Clin Biochem 56:41-46


Liu X, Swen JJ, Diekstra MHM, Boven E, Castellano D, Gelderblom H, Mathijssen RH, Vermeulen SH, Oosterwijk E, Junker K, Roessler M, Alexiusdottir K, Sverrisdottir A, Radu MT, Ambert V, Eisen T, Warren AY, Rodríguez-Antona C, García-Donás J, Koudijs KKM, Böhringer S, Kiemeney LA, Rini B, Guchelaar HJ (2018). A genetic polymorphism in CTLA-4 is associated with overall survival in sunitinib-treated patients with clear cell metastatic renal cell carcinoma. Clin Cancer Res. 24(10):2350-2356


Van Kessel KE, van der Keur KA, Dyrskjøt L, Algaba F, Welvaart NY, Beukers W, Segersten U, Keck B, Maurer T, Simic T, Horstmann M, Grimm MO, Hermann GG, Mogensen K, Hartmann A, Harving N, Petersen AC, Jensen JB, Junker K, Boormans JL, Real FX, Malats N, Malmström PU, Ørntoft TF, Zwarthoff EC (2018). Molecular markers increase precision of the European Association of Urology non-muscle invasive bladder cancer progression risk groups. Clin Cancer Res 24(7):1586-1593


Territo A, Gausa L, Alcaraz A, Musquera M, Doumerc N, Decaestecker K, Desender L, Stockle M, Janssen M, Fornara P, Mohammed N, Siena G, Serni S, Sahin S, Tuǧcu V, Basile G, Breda A (2018). The European experience on robot-assisted kidney transplantation: minimum of one-year follow-up. BJU 122(2):255-262


Siena G, Campi R, Decaestecker K, Tuğcu V, Sahin S, Alcaraz A, Musquera M, Territo A, Gausa L, Randon C, Stockle M, Janssen M, Fornara P, Mohammed N, Guirado L, Facundo C, Doumerc N, Vignolini G, Breda A, Serni S (2018). Robot-assisted Kidney Transplantation with Regional Hypothermia Using Grafts with Multiple Vessels After Extracorporeal Vascular Reconstruction: Results from the European Association of Urology Robotic Urology Section Working Group. Eur Urol Focus. 4(2):175-184


Wemmert S, Linxweiler M, Lerner C, Bochen F, Kulas P, Linxweiler J, Smola S, Urbschat S, Wagenpfeil S, Schick B (2018). Combinational chromosomal aneuploidies and HPV status for prediction of head and neck squamous cell carcinoma prognosis in biopsies and cytological preparations. J Cancer Res Clin Oncol. 144(6):1129-1141

Publikationen 2017

Linxweiler J, Körbel C, Müller A, Jüngel E, Blaheta R, Heinzelmann J, Stöckle M, Junker K, Menger MD, Saar M (2017). Experimental imaging in orthotopic renal cell carcinoma xenograft models: comparative evaluation of high-resolution 3D ultrasonography, in-vivo micro-CT and 9.4T MRI. Sci Rep.27;7(1):14249


Junker K, Hölters S, Hartmann A (2017). Human Papilloma Virus, Histopathological, and Molecular Subtyping in Penile Cancer: Relevance for Prognosis and Therapy. Eur Urol Suppl


Ohlmann CH, Miller K, Gschwend J (2017). Androgen deprivation plus abiraterone/ prednisone in metastatic hormone-sensitive prostate cancer : Joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO). Urologe A.


Baumgart S, Hölters S, Ohlmann CH, Bohle R, Stöckle M, Stampe Ostenfeld M, Dyrskjøt L, Junker K, Heinzelmann J (2017). Exosomes of invasive urothelial carcinoma cells are characterized by a specific miRNA expression signature. Oncotarget 2017


de Mello Martins AGG, Allegretta G, Unteregger G, Haupenthal J, Eberhard J, Hoffmann M, van der Zee JA, Junker K, Stöckle M, Müller R, Hartmann RW, Ohlmann CH (2017). CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone. J Steroid Biochem Mol Biol.


Ohlmann CH, Thelen P (2017). Antihormonal therapy in prostate cancer: Side effects. Urologe A.


Junker K, Ohlmann CH (2017). Re: Clonal Evolution of Chemotherapy-resistant Urothelial Carcinoma. Eur Urol.


Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, Stöckle M (2017). Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial. Trials.4;18(1):457

Ohlmann CH (2107). Patients with metastatic prostate cancer: Recommendations for primary hormonal or chemohormonal therapy. Urologe A.


Hussein AA, Saar M, May PR, Wijburg CJ, Richstone L, Wagner A, Wilson T, Yuh B, Redorta JP, Dasgupta P, Shamim Khan M, Menon M, Peabody JO, Hosseini A, Gaboardi F, Mottrie A, Rha KH, Hemal A, Stockle M, Kelly J, Maatman TJ, Canda AE, Wiklund P, Guru KA(2017). Early Oncologic Failure after Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. J Urol.


van der Zanden LF, Vermeulen SH, Oskarsdottir A, Maurits JS, Diekstra MH, Ambert V, Cambon-Thomsen A, Castellano D, Fritsch A, Garcia Donas J, Guarch Troyas R, Guchelaar HJ, Hartmann A, Hulsbergen-van de Kaa C, Jaehde U, Junker K, Martinez-Cardus A, Masson G, Oosterwijk-Wakka J, Radu MT, Rafnar T, Rodriguez-Antona C, Roessler M, Ruijtenbeek R, Stefansson K, Warren A, Wessels L, Eisen T, Kiemeney LA, Oosterwijk E (2017). Urol Oncol.


Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K; Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group (2017). Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. Eur Urol Focus. pii: S2405-4569(17)30125-6.


Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG, Mogensen K, Beukers W, Marquez M, Segersten U, Høyer S, Ulhøi BP, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic C, Simic T, Junker K, Harving N, Petersen AC, Jensen JB, Keck B, Grimm MO, Horstmann M, Maurer T, Steyerberg EW, Zwarthoff EC, Real FX, Malats N, Malmström PU, Ørntoft TF (2017). Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. Eur Urol.


Hussein AA, May PR, Ahmed YE, Saar M, Wijburg CJ, Richstone L, Wagner A, Wilson T, Yuh B, Redorta JP, Dasgupta P, Kawa O, Khan MS, Menon M, Peabody JO, Hosseini A, Gaboardi F, Pini G, Schanne F, Mottrie A, Rha KH, Hemal A, Stockle M, Kelly J, Tan WS, Maatman TJ, Poulakis V, Kaouk J, Canda AE, Balbay MD, Wiklund P, Guru KA (2017). Development of a Patient and Institutional-Based Model for Estimation of Operative Times for Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. BJU Int.


Eisenbeis J, Peisker H, Backes CS, Bur S, Hölters S, Thewes N, Greiner M, Junker C, Schwarz EC, Hoth M, Junker K, Preissner KT, Jacobs K, Herrmann M, Bischoff M (2017). The extracellular adherence protein (Eap) of Staphylococcus aureus acts as a proliferation and migration repressing factor that alters the cell morphology of keratinocytes. Int J Med Microbiol. 307(2):116-125

Publikationen 2016

Niklas C, Saar M, Berg B, Steiner K, Janssen M, Siemer S, Stöckle M, Ohlmann CH (2016). da Vinci and Open Radical Prostatectomy: Comparison of Clinical Outcomes and Analysis of Insurance Costs. Urol Int. 96(3):287-94

Fizazi K, Flaig TW, Stöckle M, Scher HI, de Bono JS, Rathkopf DE, Ryan CJ, Kheoh T, Li J, Todd MB, Griffin TW, Molina A, Ohlmann CH (2016). Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol. 27(4):699-705

Schubert M, Junker K, Heinzelmann J (2016). Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development? J Cancer Res Clin Oncol. 142(8), 1673-1695

Junker K, Heinzelmann J, Beckham C, Ochiya T, Jenster G (2016). Extracellular Vesicles and Their Role in Urologic Malignancies. Eur Urol. 70(2):323-31.

Ohlmann CH, Stöckle M, Albers P, Schmidberger H, Härter M, Kristiansen G, Martus P, Wellek S, Bussar-Maatz R, Wiegel T (2016). PREFERE - Study on the rise. Urologe A; 55(3):313-7

Awwad HM, Ohlmann CH, Stoeckle M, Aziz R, Geisel J, Obeid R (2016). Choline-phospholipids inter-conversion is altered in elderly patients with prostate cancer. Biochimie. 126:108-14

Probst KA, Ohlmann CH, Saar M, Siemer S, Stoeckle M, Janssen M (2016). Robotic-assisted vs. open adrenalectomy: evaluation of cost effectiveness and perioperative outcome. BJU Int. 118(6):952-957

Ohlmann CH, Gschwend J, Miller K (2016). Drug therapy of hormone-sensitive metastatic prostate cancer : Consensus paper of the AKO/AUO. Urologe A. 55(9):1164-72

Lerner C, Wemmert S, Bochen F, Kulas P, Linxweiler M, Hasenfus A, Heinzelmann J, Leidinger P, Backes C, Meese E, Urbschat S, Schick B (2016). Characterization of miR-146a and miR-155 in blood, tissue and cell lines of head and neck squamous cell carcinoma patients and their impact on cell proliferation and migration. J Cancer Res Clin Oncol. 142(4):757-66

Dornbusch J, Walter M, Gottschalk A, Obaje A, Junker K, Ohlmann CH, Meinhardt M, Zacharis A, Zastrow S, Schoffer O, Grimm MO, Klug SJ, Wirth MP, Fuessel S (2016). Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients. J Cancer Res Clin Oncol.     142(6):1171-82

Stoehr CG, Stoehr R, Wenners A, Hartmann A, Bertz S, Spath V, Walter B, Junker K, Moch H, Hinze R, Denzinger S, Bond EE, Bond GL, Bluemke K, Weigelt K, Lieb V, Nolte E, Fornara P, Wullich B, Taubert H, Wach S (2016). Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients. Oncogenesis; 5:e205

Valta MP, Zhao H, Saar M, Tuomela J, Nolley R, Linxweiler J, Sandholm J, Lehtimäki J, Härkönen P, Coleman I, Nelson PS, Corey E, Peehl DM (2016). Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer. Clin Exp Metastasis. 33(4):325-37

Stoehr CG, Walter B, Denzinger S, Ghiorzo P, Sturm RA, Hinze R, Moch H, Junker K, Hartmann A, Stoehr R (2016). Pathobiology; 83(4):113-117.

Mulhall JP, Brock G, Oelke M, Fode M, Probst KA, Henneges C, d'Anzeo G, Rossi A, Büttner H (2016). Effects of Tadalafil Once-Daily or On-Demand vs Placebo on Return to Baseline Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy - Results from a Randomized Controlled Trial (REACTT). J Sex Med. 2016 Apr;13(4):679-83

Dieckmann KP, Dralle-Filiz I, Matthies C, Heinzelbecker J, Bedke J, Ellinger J, Anheuser P, Souchon R, Pichlmeier U; German Testicular Cancer Study Group (2016). Testicular seminoma clinical stage 1: treatment outcome on a routine care level. J Cancer Res Clin Oncol.     142(7):1599-607

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MB, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KE, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L (2016). Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell. 30(1):27-42

Winter S, Fisel P, Büttner F, Rausch S, D'Amico D, Hennenlotter J, Kruck S, Nies AT, Stenzl A, Junker K, Scharpf M, Hofmann U, van der Kuip H, Fend F, Ott G, Agaimy A, Hartmann A, Bedke J, Schwab M, Schaeffeler E (2016). Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. Sci Rep. 20;6:29930

Collins JW, Patel H, Adding C, Annerstedt M, Dasgupta P, Khan SM, Artibani W, Gaston R, Piechaud T, Catto JW, Koupparis A, Rowe E, Perry M, Issa R, McGrath J, Kelly J, Schumacher M, Wijburg C, Canda AE, Balbay MD, Decaestecker K, Schwentner C, Stenzl A, Edeling S, Pokupić S, Stockle M, Siemer S, Sanchez-Salas R, Cathelineau X, Weston R, Johnson M, D'Hondt F, Mottrie A, Hosseini A, Wiklund PN (2016). Enhanced Recovery After Robot-assisted Radical Cystectomy: EAU Robotic Urology Section Scientific Working Group Consensus View. Eur Urol. 70(4):649-660

Publikationen 2015

Bütow Z, Schunk S, Janssen M, Gräber S, Saar M, Kamradt J, Siemer S, Stöckle M, Ohlmann CH (2015). Quality of Preoperative Biopsy Is a Risk Factor for Positive Surgical Margins in Organ-Confined Prostate Cancer Treated with Nerve-Sparing Robot-Assisted Radical Prostatectomy. Urol Int.


Ohlmann CH (2015). Chemotherapy of prostate cancer. Urologe A. 54(10):1461-70.

Ohlmann CH, Gschwend J, Miller K; Mitglieder von AKO und die Vorstandsmitglieder der AUO (2015). Combined chemohormonal therapy for metastatic hormone-sensitive prostate cancer : Effectiveness and update as a joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)]. Urologe A. 54(11):1606-8


Ohlmann CH, Stöckle M (2015). Comment re: Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial. Lancet Oncol 2015;16:76-86. Eur Urol.

Janssen M, Becker F (2015). Re: Regional Geographic Variations in Kidney Cancer Incidence Rates in European Countries. Eur Urol. 2015 Aug;68(2):335-6


Heinzelmann J, Stubendorff B, Jung V, Baumgart S, Hölters S, Unteregger G, Grimm J, Linxweiler J, Janssen M, Ohlmann CH, Saar M, Siemer S, Stöckle M, Junker K (2015). Epigenetic regulation of urological tumors : Importance for prognosis and metastasis. Urologe A

Saar M, Körbel C, Linxweiler J, Jung V, Kamradt J, Hasenfus A, Stöckle M, Unteregger G, Menger MD (2015). Orthotopic tumorgrafts in nude mice: A new method to study human prostate cancer. Prostate


Ohlmann CH*, Brecht IB*, Junker K, van der Zee JA, Nistor A, Bohle RM, Stöckle M, Metzler M, Hartmann A, Agaimy A (2015). Sclerosing epithelioid fibrosarcoma of the kidney: clinicopathologic and molecular study of a rare neoplasm at a novel location. Ann Diagn Pathol. * equally contributed


Ohlmann CH, Duensing S, Eichenauer R, König F, Machtens S, Schostak M, Thomas C, Albers P (2105). Metastasized prostate cancer : Position paper on the use of chemotherapy. Urologe A


Molitor M, Junker K, Eltze E, Toma M, Denzinger S, Siegert S, Knuechel R, Gaisa NT (2015). Comparison of structural genetics of non-schistosoma-associated squamous cell carcinoma of the urinary bladder. Int J Clin Exp Pathol. 8(7):8143-58


Pfestroff A, Luster M, Jilg CA, Olbert PJ, Ohlmann CH, Lassmann M, Maecke HR, Ezziddin S, Bodei L; Radionuclide Therapy Committee of the European Association of Nuclear Medicine (2015). Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks. Eur J Nucl Med Mol Imaging.


Ganzer R, Franz T, Rai BP, Siemer S, Stolzenburg JU (2015). Management of ureteral strictures and hydronephrosis. Urologe A. 54(8):1147-56


Taubert H, Wach S, Jung R, Pugia M, B BK, Bertz S, Nolte E, Stoehr R, Lehmann J, Ohlmann CH, Stöckle M, Wullich B, Hartmann A (2015). Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients. Mol Med.

Büttner F, Winter S, Rausch S, Reustle A, Kruck S, Junker K, Stenzl A, Agaimy A, Hartmann A, Bedke J, Schwab M, Schaeffeler E (2015). Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron. Eur Urol.


Körbel C, Jung V, Kamradt J, Stöckle M, Unteregger G, Menger MD, Saar M (2015). High-Resolution Ultrasound Allows Percutaneous Initiation and Surveillance of Prostate Cancer in an Orthotopic Murine Model. Urol Int.; 94(3):347-353


Ahmed K, Khan R, Mottrie A, Lovegrove C, Abaza R, Ahlawat R, Ahlering T, Ahlgren G, Artibani W, Barret E, Cathelineau X, Challacombe B, Coloby P, Hubert J, Khan MS, Michel MS, Montorsi F, Murphy D, Palou J, Patel V, Piechaud PT, Van Poppel H, Rischmann P, Sanchez-Salas R, Siemer S, Stoeckle M, Stolzenburg JU, Terrier JE, Thueroff J, Christophe CV, Van Der Poel HG, Van Cleynenbreugel B, Volpe A, Wagner C, Wiklund P, Wilson T, Wirth M, Witt J, Dasgupta P (2015). Development Of A Standardised Training Curriculum For Robotic Surgery: A Consensus Statement From An International Multidisciplinary Group Of Experts. BJU Int.


Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow A, Wirth M, Störkel S, Golz R, Engenhart-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K (2015). Prostate-Specific Antigen Persistence After Radical Prostatectomy as a Predictive Factor of Clinical Relapse-Free Survival and Overall Survival: 10-Year Data of the ARO 96-02 Trial. Int J Radiat Oncol Biol Phys. 91(2):288-94


Wiegel T, Stöckle M, Bartkowiak D (2015). PREFEREnce-based Randomized Evaluation of Treatment Modalities in Low or Early Intermediate-risk Prostate Cancer. Eur Urol: 67(1):1-2


Brenner W, Haber T, Junker K, Roos F, Thüroff JW (2015). Bone metastasis by renal cell carcinoma : Importance of calcium and calcium-sensing receptor. Urologe A.


Haber T, Jöckel E, Roos FC, Junker K, Prawitt D, Hampel C, Thüroff JW, Brenner W (2015). Bone metastasis in renal cell carcinoma is preprogrammed in the primary tumor and caused by AKT and integrin alpha5 signaling. J Urol


Rogler A, Kendziorra E, Giedl J, Stoehr C, Taubert H, Goebell PJ, Wullich B, Stöckle M, Lehmann J, Petsch S, Hartmann A, Stoehr R (2015). Functional analyses and prognostic significance of SFRP1 expression in bladder cancer. J Cancer Res Clin Oncol


Raza SJ, Wilson T, Peabody JO, Wiklund P, Scherr DS, Al-Daghmin A, Dibaj S, Khan MS, Dasgupta P, Mottrie A, Menon M, Yuh B, Richstone L, Saar M, Stoeckle M, Hosseini A, Kaouk J, Mohler JL, Rha KH, Wilding G, Guru KA (2015). Long-term Oncologic Outcomes Following Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. Eur Urol


Grimm S, Jennek S, Singh R, Enkelmann A, Junker K, Rippaus N, Berndt A, Friedrich K (2105). Malignancy of bladder cancer cells is enhanced by tumor-associated fibroblasts through a multifaceted cytokine-chemokine loop. Exp Cell Res


Niegisch G, Retz M, Thalgott M, Balabanov S, Honecker F, Ohlmann CH, Stöckle M, Bögemann M, Vom Dorp F, Gschwend J, Hartmann A, Ohmann C, Albers P(2015). Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09). Oncology


Olbert PJ, Ohlmann CH, Schwentner C (2015). Therapy of low-grade nonmuscle-invasive bladder cancer. Urologe A


Sänger S, Wiegel T, Stöckle M, Härter M, Bergelt C (2015). Development of patient education materials for the "German Prostate Cancer Trial PREFERE". Z Evid Fortbild Qual Gesundhwes; 109(1):28-39

Publikationen 2014

Heinzelmann J, Unrein A, Wickmann U, Baumgart S, Stapf M, Szendroi A, Grimm MO, Gajda MR, Wunderlich H, Junker K (2014). MicroRNAs with Prognostic Potential for Metastasis in Clear Cell Renal Cell Carcinoma: A Comparison of Primary Tumors and Distant Metastases. Ann Surg Oncol. 21(3):1046-54


Steffens* S, Junker* K, Roos* FC, Janssen* M, Becker F, Henn D, Wegener G, Siemer S, Hofmann R, Schrader M, Stöckle M, Thüroff JW, Hartmann A, Kuczyk MA, Schrader AJ; German Renal Tumor Network (2014). Small renal cell carcinomas - How dangerous are they really? Results of a large multicenter study. Eur J Cancer 50(4):739-45 * equally contributed


Schrader AJ*, Boegemann M*, Ohlmann CH*, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV (2013). Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone. Eur Urol. 65(1):30-6   *Contributed equally


Saar M, Kamradt J, Sauer C, Stöckle M, Grobholz R (2014). Margin status of the vas deferens in radical prostatectomy specimens. Relevance or waste of time? Histopathology. 65(1):45-50


Stubendorff B, Finke S, Walter M, Kniemeyer O, von Eggeling F, Gruschwitz T, Steiner T, Ott U, Wolf G, Wunderlich H, Junker K (2014). Urine protein profiling identified alpha-1-microglobulin and haptoglobin as biomarkers for early diagnosis of acute allograft rejection following kidney transplantation. World J Urol. 32(6):1619-24


Saar M, Zhao H, Nolley R, Young SR, Coleman I, Nelson PS, Vessella RL, Peehl DM (2014). Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. Cancer Lett. 351(2):272-80


Sanjmyatav J, Matthes S, Muehr M, Sava D, Sternal M, Wunderlich H, Gajda M, Grimm MO, Junker K (2014). Identification of high-risk patients with clear cell renal cell carcinoma based on interphase-FISH. Br J Cancer. 110(10):2537-43


Gruschwitz T1, Gajda M, Enkelmann A, Grimm MO, Wunderlich H, Horstmann M, Junker K (2014). FISH analysis of washing urine from the upper urinary tract for the detection of urothelial cancers. Int Urol Nephrol;46(9):1769-74


Hartmann A, Schlomm T, Bertz S, Heinzelmann J, Hölters S, Simon R, Stoehr R, Junker K (2014). Prognostic and predictive molecular markers for urologic cancers. Urologe A, 53(4):491-500


Roos* FC, Steffens* S, Junker K*, Janssen* M, Becker F, Wegener G, Brenner W, Steinestel J, Schnoeller TJ, Schrader M, Hofmann R, Thüroff JW, Kuczyk MA, Wunderlich H, Siemer S, Hartmann A, Stöckle M, Schrader AJ (2014). Survival advantage of partial over radical nephrectomy in patients presenting with localized renal cell carcinoma. BMC Cancer 14(1):372 * equally contributed


Steffens S*, Roos FC*, Janssen M*, Becker F, Steinestel J, Abbas M, Steinestel K, Wegener G, Siemer S, Thüroff JW, Hofmann R, Stöckle M, Schrader M, Hartmann A, Junker K, Kuczyk MA, Schrader AJ; For the German Renal Cell Cancer Network (2014). Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size. Virchows Arch: 465(4):439-44 * equally contributed


Junker K (2014). Possibilities of Molecular Diagnosis of Renal Cell Carcinoma. Aktuelle Urol; 45(5):370-373


Steffens S*, Janssen M*, Roos FC*, Becker F, Steinestel J, Abbas M, Steinestel K, Wegener G, Siemer S, Thüroff JW, Hofmann R, Stöckle M, Schrader M, Hartmann A, Hasenfus A, Kuczyk MA, Junker K, Schrader AJ; German Renal Cell Cancer Network (2014). The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma. Hum Pathol:  45(12):2411-6 * equally contributed


Saar M, Ohlmann CH, Janssen M, Stöckle M, Siemer S (2014). [Radical prostatectomy: Detection and management of intra- and postoperative complications].Urologe A; 53(7):976-83


Probst KA, Böhm K, Borgmann H, Beyer B (2014). YouTube & Co: Welche Bedeutung haben Videoportale in der modernen Medizin? Urologe A;53(6):888-9.


Bergmann L, Beck J, Bothe K, Brinkmann OA, Buse S, Goebell PJ, Grünwald V, Holzapfel K, Kübler H, Marschner NW, Mickisch G, Schultze-Seemann W, Siebels M, Siemer S, Störkel S, Gschwend JE (2014). Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practice. Oncol Res Treat. 37(3):136-41.


Schmidt T1, Adam C, Hirsch HH, Janssen MW, Wolf M, Dirks J, Kardas P, Ahlenstiel-Grunow T, Pape L, Rohrer T, Fliser D, Sester M, Sester U (2014). BK Polyomavirus-Specific Cellular Immune Responses Are Age-Dependent and Strongly Correlate With Phases of Virus Replication. Am J Transplant. 14(6):1334-45


Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, Santos J, Peehl DM (2014). Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer;  134(10):2322-9


Valta MP, Zhao H, Ingels A, Thong AE, Nolley R, Saar M, Peehl DM (2014). Development of a realistic in vivo bone metastasis model of human renal cell carcinoma. Clin Exp Metastasis; 31(5):573-84.


Raza SJ, Field E, Kibel AS, Mottrie A, Weizer AZ, Wagner A, Hemal AK, Scherr DS, Schanne F, Gaboardi F, Wu G, Peabody JO, Koauk J, Redorta JP, Pattaras JG, Rha KH, Richstone L, Balbay MD, Menon M, Hayn M, Stoeckle M, Wiklund P, Dasgupta P, Pruthi R, Ghavamian R, Khan S, Siemer S, Maatman T, Wilson T, Poulakis V, Wilding G, Guru KA (2014). International Robotic Radical Cystectomy Consortium: A way forward. Indian J Urol;30:314-7


Al-Daghmin A, Kauffman EC, Shi Y, Badani K, Balbay MD, Canda E, Dasgupta P, Ghavamian R, Grubb R 3rd, Hemal A, Kaouk J, Kibel AS, Maatman T, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi R, Redorta JP, Rha KH, Richstone L, Schanne F, Scherr DS, Siemer S, Stöckle M, Wallen EM, Weizer A, Wiklund P, Wilson T, Wilding G, Woods M, Guru KA (2014). Efficacy of Robot-assisted Radical Cystectomy in Advanced Bladder Cancer: Results from the International Radical Cystectomy Consortium (IRCC). BJU Int. 114(1):98-103


Goebell PJ, Kamat AM, Sylvester RJ, Black P, Droller M, Godoy G, Hudson MA, Junker K, Kassouf W, Knowles MA, Schulz WA, Seiler R, Schmitz-Dräger BJ (2014). Assessing the quality of studies on the diagnostic accuracy of tumor markers. Urol Oncol: 32(7):1051-1060


Wiechno P, Somer BG, Mellado B, Chłosta PL, Cervera Grau JM, Castellano D, Reuter C, Stöckle M, Kamradt J, Pikiel J, Durán I, Wedel S, Callies S, André V, Hurt K, Brown J, Lahn M, Heinrich B (2014). A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer. Eur Urol, 65(3):516-20


Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Stöckle M, Rübe C, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K (2014). Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy:  10-year Follow-up of the ARO 96-02/AUO AP 09/95 Trial. Eur Urol: 66(2):243-50


Al Kadah B, Siemer S, Schick B (2014). First Experience in the Thyroid and Parathyroid Surgery Using the da Vinci® System. Laryngorhinootologie, 93(1):25-9


Krege S, Rexer H, Vom Dorp F, de Geeter P, Klotz T, Retz M, Heidenreich A, Kühn M, Kamradt J, Feyerabend S, Wülfing C, Zastrow S, Albers P, Hakenberg O, Roigas J, Fenner M, Heinzer H, Schrader M (2014). Prospective randomized double-blind multicenter phase II study comparing chemotherapy with gemcitabine and cisplatin plus sorafenib vs gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer - SUSE - (AUO-AB 31/05). BJU Int, 113(3):429-36


Joeckel E, Haber T, Prawitt D, Junker K, Hampel C, Thüroff JW, Roos FC, Brenner W (2014). High calcium concentration in bones promotes bone metastasis in renal cell carcinomas expressing calcium-sensing receptor. Mol Cancer. 13:42


Pu K, Shuhendler AJ, Valta MP, Cui L, Saar M, Peehl DM, Rao J (2014). Phosphorylcholine-Coated Semiconducting Polymer Nanoparticles as Rapid and Efficient Labeling Agents for In Vivo Cell Tracking. Adv Healthc Mater. 3(8):1292-8


Rogler A, Hoja S, Giedl J, Ekici AB, Wach S, Taubert H, Goebell PJ, Wullich B, Stöckle M, Lehmann J, Petsch S, Hartmann A, Stoehr R (2014). Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study. BMC Cancer; 14:214


Ahmed K, Khan SA, Hayn MH, Agarwal PK, Badani KK, Balbay MD, Castle EP, Dasgupta P, Ghavamian R, Guru KA, Hemal AK, Hollenbeck BK, Kibel AS, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi RS, Redorta JP, Rha KH, Richstone L, Saar M, Scherr DS, Siemer S, Stoeckle M, Wallen EM, Weizer AZ, Wiklund P, Wilson T, Woods M, Khan MS (2014). Analysis of Intracorporeal Compared with Extracorporeal Urinary Diversion After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. Eur Urol. 65(2):340-7


von Klot CA, Kramer MW, Böker A, Herrmann TR, Peters I, Kuczyk MA, Ligges U, Gschwend JE, Retz M, Schmid SC, Stenzl A, Schwentner C, Todenhöfer T, Stöckle M, Ohlmann CH, Azone I, Mager R, Bartsch G, Haferkamp A, Heidenreich A, Piper C, Merseburger AS (2014). Is there an anti-androgen withdrawal syndrome for enzalutamide? World J Urol; 2(5):1171-6


Leyking S, Poppleton A, Sester U, Ohlmann CH, Stöckle M, Fliser D, Klingele M (2014). Kidney transplantation from a deceased donor with anuric acute kidney injury caused by rhabdomyolysis. Transplantation: 98(10):e87-8

Publikationen 2013

Borgmann H, Wölm JH, Probst K, Salem J (2013). Urology 2.0 - new social media in urology. Urologe A;52(10):1451-3


Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. ….

Boyce A, Costello A, Davis I, Ganju V, Horvath L, Lynch R, Marx G, Parnis F, Shapiro J, Singhal N, Slancar M, Van Hazel G, Wong S, Yip D, Carpentier P, Luyten D, Rottey S, Van Aelst F, Cheng T, Chin J, Ellard S, Fradet Y, Gleave M, Joshua A, Klotz L, Martins H, North S, Abdel-Hamid S, Colombel M, Fléchon A, Haillot O, Joly F, Oudard S, Priou F, Raymond E, Albers P, Boegemann M, Gleissner J, Gschwend J, Hammerer P, Heidenreich A, Kuczyk M, Miller K, Oetzel R, Roigas J, Steuber T, Stöckle M, Wirth M, Papandreou C, Bracarda S, Marcello T, Sternberg C, Bangma C, de Reijke T, Arija J, Bellmunt J, Lopez R, Lopez-Brea M, Bjartell A, Damber J, Haggman M, Hellstrom M, Seke M, Brown J, Chowdhury S, Elliott T, Harland S, Innes H, James N, Jones R, Mazhar D, Paez E, Protheroe A, Staffurth J, Ahmann F, Andriole G, Arrowsmith E, Assikis V, Baron A, Berry W, Bubley G, Carney J, Chu L, Cosgriff T, Denmeade S, Deshpande H, Duchene D, Ferrari A, Frenkel E, Gabrail N, Garcia J, George D, Gomella L, Goodman O, Gore I, Gullo J, Hainsworth J, Hamid O, Hutson T, King D, Koh H, Koletsky A, Kudrik F, Lara P, Lyons R, Maranchie J, Modiano M, Nieva J, Nordquist L, Pinski J, Poiesz B, Polikoff J, Quinn D, Redfern C, Riggs S, Ryan C, Saleh M, Sartor A, Scholz M, Shore N, Srinivas S, Vaishampaya U, Vieweg J, Vira M, Vogelzang N, Wilding G, Wong Y, Belldegrun A, Kantoff PW, Carducci MA, Vogelzang NJ, Kelly WK, Auchus RJ, Meyers M, Rackoff W, Tran N, Yu M, Knoblauch R, Naini V, Matheny S, Maul S, Larsen J, Martin J, Wawda H, Goffredo D, Li J, Li S, Li B, Durve K, Morris MJ, Larson SM (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med, 368(2):138-48.


Junker K, Ficarra V, Kwon ED, Leibovich BC, Thompson RH, Oosterwijk E (2013). Potential role of genetic markers in the management of kidney cancer. Eur Urol; 63(2):333-40


Treiyer A, Janssen M, Kamradt J, Siemer S, Stöckle M (2013). Initial experience of a series of robotic-assisted laparoscopic adrenalectomy. Actas Urol Esp; 37(1):54-59


Johar RS, Hayn MH, Stegemann AP, Ahmed K, Agarwal P, Balbay MD, Hemal A, Kibel AS, Muhletaler F, Nepple K, Pattaras JG, Peabody JO, Palou Redorta J, Rha KH, Richstone L, Saar M, Schanne F, Scherr DS, Siemer S, Stoeckle M, Weizer A, Wiklund P, Wilson T, Woods M, Yuh B, Guru KA (2013). Complications After Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. Eur Urol, 64(1):52-7


Keck B, Wach S, Stoehr R, Kunath F, Bertz S, Lehmann J, Stöckle M, Taubert H, Wullich B, Hartmann A (2013). Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. BMC Cancer 8;13(1):71.


Marshall SJ, Hayn MH, Stegemann AP, Agarwal PK, Badani KK, Balbay MD, Dasgupta P, Hemal AK, Hollenbeck BK, Kibel AS, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi RS, Palou Redorta J, Rha KH, Richstone L, Schanne F, Scherr DS, Siemer S, Stöckle M, Wallen EM, Weizer AZ, Wiklund P, Wilson T, Woods M, Guru KA (2013). Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC). BJU Int.  111(7):1075-80


Ficarra V, Wiklund PN, Rochat CH, Dasgupta P, Challacombe BJ, Sooriakumaran P, Siemer S, Suardi N, Novara G, Mottrie A (2013). The European Association of Urology Robotic Urology Section (ERUS) survey of robot-assisted radical prostatectomy (RARP). BJU Int. 111: 596-603


Wiegel T, Albers P, Bussar-Maatz R, Gottberg A, Härter M, Kieser M, Kristiansen G, Nettekoven G, Martus P, Schmidberger H, Wellek S, Stöckle M (2013). PREFERE - the German prostatic cancer study : Questions and claims surrounding study initiation in January 2013. Urologe A 52(4):576-9


Kristiansen G, Stöckle M, Albers P, Schmidberger H, Martus P, Wellek S, Härter M, Bussar-Maatz R, Wiegel T (2013). The importance of pathology in the German prostate cancer study PREFERE. Pathologe; 34: 449-62


Ohlmann CH (2013). Bone metastases. Aktuelle Urol; 44(2): 141-9


Feola A, Cimini A, Migliucci F, Iorio R, Zucchegna C, Rothenberger R, Cito L, Porcellini A, Unteregger G, Tombolini V, Giordano A, Di Domenico M (2013). The inhibition of p85αPI3KSer83 phosphorylation prevents cell proliferation and invasion in prostate cancer cells. J Cell Biochem, 114(9):2114-9


Sanjmyatav J, Hauke S, Gajda M, Hartmann A, Moch H, Meyer B, Pryalukhin A, Grimm MO, Junker K (2013). Establishment of a Multicolour Fluorescence In Situ Hybridisation-based Assay for Subtyping of Renal Cell Tumours. Eur Urol, 64(4):689-91


Saar M, Ohlmann CH, Siemer S, Lehmann J, Becker F, Stöckle M, Kamradt J (2013). Fast-track rehabilitation after robot-assisted laparoscopic cystectomy accelerates postoperative recovery. BJU Int;112(2):E99-E106.


Young SR, Saar M, Santos J, Nguyen HM, Vessella RL, Peehl DM (2013).Establishment and serial passage of cell cultures derived from LuCaP xenografts. Prostate (Epub ahead of print)


Keck B, Wach S, Goebell PJ, Kunath F, Bertz S, Lehmann J, Stöckle M, Taubert H, Wullich B, Hartmann A(2013). SNAI1 Protein Expression is an Independent Negative Prognosticator in Muscle-Invasive Bladder Cancer. Ann Surg Oncol.; 20:3669-74


Elsäßer J, Janssen MW, Becker F, Suttmann H, Schmitt K, Sester U, Stöckle M, Sester M (2013). Antigen-Specific CD4 T Cells Are Induced after Intravesical BCG-Instillation Therapy in Patients with Bladder Cancer and Show Similar Cytokine Profiles as in Active Tuberculosis. PLoS One. 8(9):e69892


Schroeder A, Stöckle M (2013). Perspectives for development of German urology. Urologe A;52(8):1055-6


Ohlmann CH (2013). Prostatakarzinom - PSA-Screening reduziert Risiko der Metastasenbildung. Aktuelle Uro;44(4):256-7


Becker F*, Junker K*, Parr M, Hartmann A, Füssel S, Toma M, Grobholz R, Pflugmann T, Wullich B, Strauss A, Behnes CL, Otto W, Stöckle M, Jung V (2013). Collecting duct carcinomas represent a unique tumor entity based on genetic alterations. PLoS One; 22;8(10):e78137        * authors are equally contributed


Ohlmann CH, De Santis M (2013). Neoadjuvant, inductive or adjuvant chemotherapy of bladder cancer. Urologe A;52(11):1534-40


Al-Daghmin A, Kauffman EC, Shi Y, Badani K, Balbay MD, Canda E, Dasgupta P, Ghavamian R, Grubb R 3rd, Hemal A, Kaouk J, Kibel AS, Maatman T, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi R, Redorta JP, Rha KH, Richstone L, Schanne F, Scherr DS, Siemer S, Stöckle M, Wallen EM, Weizer A, Wiklund P, Wilson T, Wilding G, Woods M, Guru KA (2013. Efficacy of Robot-assisted Radical Cystectomy in Advanced Bladder Cancer: Results from the International Radical Cystectomy Consortium (IRCC). BJU Int.


Tian J, Doi H, Saar M, Santos J, Li X, Peehl DM, Knox SJ (2013). Radioprotection and Cell Cycle Arrest of Intestinal Epithelial Cells by Darinaparsin, a Tumor Radiosensitizer. Int J Radiat Oncol Biol Phys, 87(5):1179-85


Holzmann C, Kilch T, Kappel S, Armbrüster A, Jung V, Stöckle M, Bogeski I, Schwarz EC, Peinelt C (2013). ICRAC controls the rapid androgen response in human primary prostate epithelial cells and is altered in prostate cancer. Oncotarget, 4(11):2096-107


Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-AA-301 Investigators.

Collaborators (125): Alam M, Brown M, Clingan P, Costello A, Davis I, de Souza P, Glasgow A, Horvath L, Inglis P, Lynch R, Marx G, Ng S, Nott L, Nottage M, Parnis F, Underhill C, Van Hazel G, Wong S, Janetschek G, Loidl W, Marberger M, Luyten D, Machiels J, Renard V, Rottey S, Sautois B, Schöffski P, Schrijvers D, Van Aelst F, Werbrouck P, Wynendaele W, Ernst S, Hotte S, Jancewicz M, Klotz L, Michels J, Rajan R, Wood L, Abadie S, Joly F, Kaplan R, Krakowski I, Oudard S, Rolland F, Zanetta S, Miller K, Pfister D, Stöckle M, Suttmann H, Wirth M, Salamon C, Wenczl M, Algeri R, Boni C, Conte P, Cerbone L, Villa E, Mulders P, Bird B, Breathnach O, Janku F, McCaffrey J, McDermott R, Bellmunt J, Duran I, Lluch J, Durkan G, Elliot T, Hoskin P, James N, Protheroe A, O'Sullivan J, Waxman J, Appelman L, Arrowsmith E, Assikis V, Baron A, Berry W, Burke J, Carney J, Chu L, Cohen N, Cosgriff T, Crane E, Curti B, Dakhil S, Deshpande H, Denmeade S, Ferrari A, Gabrail N, Galsky M, George D, Gore I, Hahn N, Hamid O, Harris J, Kelly W, Koletsky A, Lara P, Larson T, McClean J, Modiano M, Montgomery R, Nordquist L, Picus J, Redfern C, Rettig M, Riggs S, Rosen P, Sarantopoulos J, Sartor A, Segota Z, Shore N, Showel J, Smith M, Tagawa S, Tejwani S, Tjan-Wettstein V, Twardowski P, Vacirca J, VanVeldhuizen P, Vira M, Wong Y, Wu S, Yu E (2013).  Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer; 49(17):3648-57.

Publikationen 2012

Siemer S (2012). Partielle Nephrektomie - Kann die intraoperative Ischämie vermieden werden? Aktuelle Urol 43(6):374-5


Treiyer A, Saar M, Butow Z, Kamradt J, Siemer S, Stockle M (2012). Robotic-assisted laparoscopic radical cystectomy: Surgical and oncological outcomes. Int Braz J Urol, 38(3):324-9.


Steffens S, Janssen M, Roos FC, Becker F, Schumacher S, Seidel C, Wegener G, Thüroff JW, Hofmann R, Stöckle M, Siemer S, Schrader M, Hartmann A, Kuczyk MA, Junker K, Schrader AJ (2012). Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma - A multicentre study. Eur J Cancer; 48(15):2347-52


Jocham D, Stöckle M, Sommerauer M (2012). Aspects of bladder cancer. Urologe A; 51(6):783


Junker K, Hartmann A, Stöckle M (2012). Therapy selection in patients with advanced bladder cancer. Is molecular biology helpful? Urologe A.; 51(6):805-12


Kamradt J, Saar M, Ohlmann C, Siemer S, Stöckle M (2012). Radical cystectomy - pro robotic. Urologe A; 51(5):679-81


Ohlmann CH, Siemer S, Stöckle M (2012). Resection of metastases from prostate cancer.  Urologe A; 51(3):363-7


Ohlmann CH, Kamradt J, Stöckle M (2012). Third generation anti-androgen therapy of advanced prostate cancer. Urologe A; 51(4):522-6


Ohlmann CH, Stöckle M (2012). When should systemic chemotherapy be used for urinary bladder carcinoma? Urologe A; 51(3):325-30


Steffens S, Köhler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G, Schrader M, Kuczyk MA, Schrader AJ (2012). Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer;12(1):399


Hauser S, Wulfken LM, Holdenrieder S, Moritz R, Ohlmann CH, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel G, von Ruecker A, Müller SC, Ellinger J (2012). Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol;36(4):391-4


Ohlmann CH (2012). Zirkumzision mit Frenulumplastik. Aktuelle Urol;43(4):269-77


Ohlmann CH, Merseburger AS, Suttmann H, Schilling D, Trojan L, Kempkensteffen C, Corvin S, Mathers MJ, Bastian PJ (2012). Novel options for the treatment of castration-resistant prostate cancer. World J Urol;30(4):495-503


Linxweiler M, Linxweiler J, Barth M, Benedix J, Jung V, Kim YJ, Bohle RM, Zimmermann R, Greiner M (2012). Sec62 bridges the gap from 3q amplification to molecular cell biology in non-small cell lung cancer. Am J Pathol;180(2):473-83


Suttmann H, Saar M, Ohlmann CH, Stöckle M, Kamradt J (2012). Mistletoe extract for treatment of urological tumors. Urologe A;51(12):1656-62


Keck B, Wach S, Kunath F, Bertz S, Taubert H, Lehmann J, Stöckle M, Wullich B, Hartmann A (2012). Nuclear E-cadherin Expression is Associated with the Loss of Membranous E-cadherin, Plasmacytoid Differentiation and Reduced Overall Survival in Urothelial Carcinoma of the Bladder. Ann Surg Oncol. 2012 Oct 30. [Epub ahead of print]


Janssen M, Treiyer EA, Saar M, Ohlmann CH, Kamradt J, Junker K, Stöckle M, Siemer S (2012). Nephron-sparing surgery 2012. Aktuelle Urol; 43(6):399-402


Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301
Investigators:...... Stöckle M, .......(2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 13(10):983-92

Akçetin Z., Siemer S. (2012) Pyeloplasty - pro robotic-assisted. Urologe A; 51:640-4

Publikationen 2011

Becker F., Roos F.C., Janssen M., Brenner W., Hampel C., Siemer S., Thüroff J.W., Stöckle M. (2011) Short-term functional and oncologic outcomes of nephron-sparing surgery for renal tumours ≥ 7 cm.  Eur Urol 59:931-7

Epplen R., Stöckle M., Engelmann U., Heidenreich A., Ohlmann C.H. Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. (2011) ACTA ONCOL 50 127-33,

Furtwängler R., Nourkami N., Alkassar M., von Schweinitz D., Schenk J.P., Rübe C., Siemer S., Leuschner I., Graf N. Update on relapses in unilateral nephroblastoma registered in 3 consecutive SIOP/GPOH studies - a report from the GPOH-nephroblastoma study group. Klin Padiatr 223 113-9,

Greiner M., Kreutzer B., Jung V., Grobholz R., Hasenfus A., Stöhr R.F., Tornillo L., Dudek J., Stöckle M., Unteregger G., Kamradt J., Wullich B., Zimmermann R. (2011) Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells. Int J Cancer 128 2284-95

Greiner M., Kreutzer B., Lang S., Jung V., Cavalié A., Unteregger G., Zimmermann R., Wullich B. (2011) Sec62 protein level is crucial for the ER stress tolerance of prostate cancer. Prostate 71 1074-83

Kamradt J., Ohlmann C.H., Stöckle M. (2011) [Current developments in the diagnostics and therapy of bladder carcinoma]. Urologe A 50 Suppl 1 179-83

Ohlmann C.H., Markert E., Gerharz M., Dienes H.P., Stöckle M., Engelmann U., Heidenreich A. (2011) Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer. UROL ONCOL-SEMIN ORI 29 664-9

Retz M., Rotering J., Nawroth R., Buchner A., Stöckle M., Gschwend J.E., Lehmann J. (2011) Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow. Eur Urol 60 231-8

Saar M., Kamradt J., Jung V., Stöckle M., Unteregger G. (2011) From tumor tissue via primary cultures to xenograft models: a functional approach in prostate cancer research. Urologe A 50 961-7

Siemer S., Stöckle M. (2011) [Robotic medicine in Germany: quo vadis?]. UROLOGE 50 928-31

Smith S.C., Baras A.S., Dancik G., Ru Y., Ding K.F., Moskaluk C.A., Fradet Y., Lehmann J., Stöckle M., Hartmann A., Lee J.K., Theodorescu D. (2011) A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 12 137-43

Stöckle M. (2011) Acting in concert: comments on the article by M. Schmedders et al on different therapy approaches for prostate cancer with low risks. UROLOGE 50 944-5,

Treiyer A., Saar M., Kopper B., Kamradt J., Siemer S., Stöckle M. (2011) Robotic-assisted laparoscopic radical cystectomy: evaluation of functional and oncological results. ACTAS UROL ESP 35 152-7

Waalkes S., Becker F., Schrader A.J., Janssen M., Wegener G., Merseburger A.S., Schrader M., Hofmann R., Stöckle M., Kuczyk M.A. (2011) Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version? Eur Urol 59 258-63

Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel G, von Ruecker A, Müller SC, Ellinger J. (2011) MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One. 6:e25787.

Herrmann E, Marschner N, Grimm MO, Ohlmann CH, Hutzschenreuter U, Overkamp F,  Groschek M, Blumenstengel K, Pühse G, Steiner T. (2011) Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol. 29:361-6.

Johannsen M, Staehler M, Ohlmann CH, Flörcken A, Schmittel A, Otto T, Bex A, Hein P, Miller K, Weikert S, Grünwald V. (2011) Outcome of treatment discontinuation in  patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Ann Oncol. 22:657-63

Ohlmann CH, Markert E, Gerharz M, Dienes HP, Stöckle M, Engelmann U, Heidenreich A. (2011) Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer. Urol Oncol 29:664-9

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y,  Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. (2011) Abiraterone and  increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005


Van Poppel H, Becker F, Cadeddu JA, Gill IS, Janetschek G, Jewett MA, Laguna MP, Marberger M, Montorsi F, Polascik TJ, Ukimura O, Zhu G. (2011) Treatment of localised renal cell carcinoma. Eur Urol. 60:662-72.

Publikationen 2010

Alloussi S., Mürtz G., Braun R., Gerhardt U., Heinrich M., Hellmis E., Horn W., Marschall-Kehrel D., Niklas K., Raabe M., Rössler T., Seibt B., Siemer S., Schultz-Lampel D., Walter H., Wiedeking B., Alloussi S., Bock P., Strugala G., Madersbacher H. (2010) Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study. BJU Int 106 550-6

Herrmann E., Trojan L., Becker F., Wülfing C., Schrader A.J., Barth P., Stöckle M., Hammerschmied C.G., Staehler M., Stief C., Haferkamp A., Hohenfellner M., Legal W., Wullich B., Bolenz C., Klein T., Noldus J., Bierer S., Hertle L., Brenner W., Roos F., Michel M.S., Walter B., Wieland W., Gerss J., Otto W., Hartmann A. (2010) Prognostic factors of papillary renal cell carcinoma: results from a multi-institutional series after pathological review. J UROLOGY 183 460-6

Hoffmann A.C., Wild P., Leicht C., Bertz S., Danenberg K.D., Danenberg P.V., Stöhr R., Stöckle M., Lehmann J., Schuler M., Hartmann A. (2010) MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12 628-36

Jung V., Fischer E., Imig J., Kleber S., Nuber N., Reinshagen F., Kamradt J., Grobholz R., Knuth A., Renner C., Wadle A. (2010) Yeast-based identification of prostate tumor antigens provides an effective vaccine platform. Anticancer Res 30 895-902

Kishida T., Yao M., Uemura H., Ohlmann C., Tomita Y., Bukowski R.M., Naito S. (2010) Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy. Int J Urol 17 198-205

Mohrbach J., Janssen M.W.W., Heine G.H., Gärtner B.C., Fliser D., Sester M., Sester U. (2010) Successful outcome of kidney transplantation from a HBV-DNA positive donor into recipients with cleared HBV-infection using a pre-emptive therapy approach. J Clin Virol 49 53-7

Ohlmann C.H., Stöckle M. (2010) Diagnostic work-up and treatment of bladder cancer: current developments. Urologe A 49 172-7

Ohlmann C.H., Stöckle M. What comes after docetaxel? (2010) UROLOGE 49 64-8

Roos F.C., Rübben H., Stief C., Stöckle M., Thüroff J.W. (2010) Surgical treatment for renal cell carcinoma. AKTUEL UROL 41 252-6

Sievert K.D., Unteregger G., Nawroth R., Junker K., Becker C., Wullich B., Arbeitsgruppe urologische Forschung (AuF) Beratungs, Koordinierungsgremium des Vorstandes der Deutschen Gesellschaft für Urologie (DGU) (2010) Educational initiative of the German Society of Urology for innovative research : Workshops 2009. UROLOGE 49 91-4

Szczyrba J., Löprich E., Wach S., Jung V., Unteregger G., Barth S., Grobholz R., Wieland W., Stöhr R., Hartmann A., Wullich B., Grässer F. (2010) The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 8 529-38

Klinik für Urologie und Kinderurologie

Univ.-Prof. Dr. Michael Stöckle

Tel.: 06841 - 16 - 24702/04
Fax: 06841 - 16 - 24795

Stellv. Klinikdirektor
Prof. Dr. Stefan Siemer

Tel.: 06841 - 16 - 24702/04
Fax: 06841 - 16 - 24795

Klinik für Urologie und
Universitätsklinikum des Saarlandes
Kirrberger Straße
D-66421 Homburg/Saar